Gemeinsamer Kommentar der Deutschen Gesellschaft für Kardiologie (DGK) und der Deutschen Gesellschaft für Thorax‑, Herz- und Gefäßchirurgie (DGTHG) zu den Leitlinien (2021) der ESC/EACTS zum Management von Herzklappenerkrankungen

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab395/6358470. Zugegriffen: 28. Aug. 2021 Alashi A, Khullar T, Mentias A, Gillinov AM, Roselli EE, Svensson LG et al (2020) Long-term outcomes after aortic valve surgery in patients with asymptomatic chronic aortic regurgitation and preserved LVEF: impact of baseline and follow-up global longitudinal strain. JACC Cardiovasc Imaging 13(1):12–21 Kang D‑H, Park S‑J, Lee S‑A, Lee S, Kim D‑H, Kim H‑K et al (2020) Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med 382(2):111–119 Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R et al (2021) A ortic V alve Repl A cemen T versus conservative treatment in A symptomatic seve R e aortic stenosis: the AVATAR trial. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.121.057639 Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F et al (2021) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive summary a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. https://doi.org/10.1161/CIR.0000000000000932 Grigioni F, Clavel M‑A, Vanoverschelde J‑L, Tribouilloy C, Pizarro R, Huebner M et al (2018) The MIDA Mortality Risk Score: development and external validation of a prognostic model for early and late death in degenerative mitral regurgitation. Eur Heart J 39(15):1281–1291. https://doi.org/10.1093/eurheartj/ehx465 Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Piérard LA et al (2017) Standards defining a ‘heart valve centre’: ESC working group on valvular heart disease and European association for cardiothoracic surgery viewpoint. Eur Heart J 38(28):2177–2183. https://doi.org/10.1093/eurheartj/ehx370 Lindenfeld J, Abraham WT, Grayburn PA, Kar S, Asch FM, Lim DS et al (2021) Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: a secondary analysis of the COAPT trial. JAMA Cardiol 6(4):427–436. https://doi.org/10.1001/jamacardio.2020.7200 Karam N, Orban M, Kalbacher D, Butter C, Praz F, Lubos E et al (2021) Impact of effective regurgitant orifice area on outcome of secondary mitral regurgitation transcatheter repair. Clin Res Cardiol 110(5):732–739 Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77(3):243–255 Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379(24):2307–2318 Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374(17):1609–1620 Reardon MJ, van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376(14):1321–1331 Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG et al (2020) Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 382(9):799–809 Thyregod HGH, Ihlemann N, Jørgensen TH, Nissen H, Kjeldsen BJ, Petursson P et al (2019) Five-year clinical and echocardiographic outcomes from the NOTION randomized clinical trial in patients at lower surgical risk. Circulation 139(24):2714–2723 Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380(18):1695–1705 Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380(18):1706–1715 Siontis GCM, Praz F, Pilgrim T, Mavridis D, Verma S, Salanti G et al (2016) Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J 37(47):3503–3512. https://doi.org/10.1093/eurheartj/ehw225 Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK et al (2021) Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol 77(9):1149–1161 (https://www.sciencedirect.com/science/article/pii/S0735109721000073) Kuck K‑H, Bleiziffer S, Eggebrecht H, Ensminger S, Frerker C, Möllmann H et al (2020) Konsensuspapier der Deutschen Gesellschaft für Kardiologie (DGK) und der Deutschen Gesellschaft für Thorax‑, Herz- und Gefäßchirurgie (DGTHG) zur kathetergestützten Aortenklappenimplantation (TAVI) 2020. Kardiologe 14(3):182–204. https://doi.org/10.1007/s12181-020-00398-w Beyersdorf F, Bauer T, Freemantle N, Walther T, Frerker C, Herrmann E et al (2021) Five-year outcome in 18 010 patients from the German Aortic Valve Registry. Eur J Cardiothorac Surg 60(5):1139–1146 Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J et al (2019) Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 12(3):433–442 Kim JB, Spevack DM, Tunick PA, Bullinga JR, Kronzon I, Chinitz LA et al (2008) The effect of transvenous pacemaker and Implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study. J Am Soc Echocardiogr 21(3):284–287 Miura M, Alessandrini H, Alkhodair A, Attinger-Toller A, Biasco L, Lurz P et al (2020) Impact of massive or torrential tricuspid regurgitation in patients undergoing transcatheter tricuspid valve intervention. JACC Cardiovasc Interv 13(17):1999–2009 Rankin JS, Badhwar V, He X, Jacobs JP, Gammie JS, Furnary AP et al (2017) The society of thoracic surgeons mitral valve repair/replacement plus coronary artery bypass grafting composite score: a report of the society of thoracic surgeons quality measurement task force. Ann Thorac Surg 103(5):1475–1481 (https://www.sciencedirect.com/science/article/pii/S0003497516312875) Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M et al (2021) Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med. https://doi.org/10.1056/NEJMoa2115961 Nickenig G, Weber M, Lurz P, von Bardeleben RS, Sitges M, Sorajja P et al (2019) Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6‑month outcomes of the TRILUMINATE single-arm study. Lancet 394(10213):2002–2011 Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L et al (2019) Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 74(24):2998–3008 Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F et al (2021) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 77(4):e25–e197 Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF et al (2020) Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 383(15):1447–1457. https://doi.org/10.1056/NEJMoa2017815 Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H et al (2020) A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 382(2):120–129 van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D et al (2021) Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med 385(23):2150–2160. https://doi.org/10.1056/NEJMoa2111016 Collet JP, Berti S, Cequier A, van Belle E, Lefevre T, Leprince P et al (2018) Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. Am Heart J 200:44–50 Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF et al (2020) Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 382(18):1696–1707 (Apr)